Project Details
Description
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel
Status | Finished |
---|---|
Effective start/end date | 3/9/15 → 12/31/21 |
Funding
- Morphotek, Inc.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.